Drug Pricing & Reimbursement

MBM single industries-served drug pricing

Once a drug product receives regulatory approval from Health Canada, market access and pricing continue to be critical issues for manufacturers in Canada. Pricing is effectively controlled at two levels: the Patented Medicine Prices Review Board (PMPRB) exerts direct pricing controls over patented medicines; and the provinces and territories exert considerable pricing pressures on manufacturers through a labyrinth of reimbursement and interchangeability rules.

MBM’s experienced team of professionals provide the necessary expertise to help their clients strategically and successfully navigate through the complex patchwork of legislation, review bodies and private/public drug plans across the country to ensure that their products are marketed in a timely and profitable manner.

Submit to DiggSubmit to FacebookSubmit to Google BookmarksSubmit to StumbleuponSubmit to TwitterSubmit to LinkedIn

cb photo 91 561829f6d3c22

DR. SUZANNE HOF

Patent Agent


Suzanne focuses on the drafting and prosecuting of biochemical, pharmaceutical, chemical as well as cleantech and green technology patents.MBM read_more_btn

 

MBM logo

About MBM

 The process of invention is complete only with the IP protection provided in law. That's where MBM comes in. We match our clients' creative thinking with the creative protection needed to achieve their goals.Read More About MBM

Clarifications to the Data Protection Guidance Document

Health Canada recently announced that section 2.1 of its Guidance Document re: Data Protection has been amended to clarify that the prior approval of a medicinal ingredient in a drug for veterinary use will not preclude the granting of data protection for a drug for...Read More